Salute e Benessere

Trading in GN Store Nord shares by board members, executives and associated…

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. Details of the person discharging managerial responsibilities/person closely associated NamePeter Karlstromer Reason for the notification Position/statusChief Executive OfficerInitial...
Nasdaq GlobeNewswire
06/09/2023

Isotopia Issues a call to action to the radionuclide Therapy industry.

The Lu-177 radiopharmaceuticals sector stands at a critical juncture, necessitating urgent collaboration. Our shared duty as supply chain stewards has never been more vital. Success hinges on our ability to address this pressing matter together. The Lu-177 radiopharmaceuticals sector stands at a critical juncture, necessitating urgent collaboration. Our shared duty as supply chain stewards has never been more vital. Success hinges on our ability to address this pressing matter together...
PR Newswire
06/09/2023

Teikoku Pharma USA announces positive topline results from Phase 2 clinical…

The new analysis shows that treatment with TPU-006 resulted in statistically significantly lower pain scores and reduced use of opioid rescue medication compared with placebo. TPU-006 was well tolerated with no unexpected adverse events, little application site skin irritation, and minimal drowsiness. Patients treated with TPU-006 experienced less constipation and nausea likely due to reduced use of opioid rescue medication. The new analysis shows that treatment with TPU-006 resulted in...
PR Newswire
06/09/2023

AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in…

LONDON, Sept. 6, 2023 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held clinical-stage specialty biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, today announced results from the company's REACH-CDM clinical study of the investigational therapy AMO-02 in the treatment of children and adolescents with congenital myotonic dystrophy. Results will be reviewed on Saturday, September 9 at 3:30 PM ET in a…
PR Newswire
06/09/2023

VentureMed Group Receives European Medical Device Regulation (MDR) Certification…

"MDR certification demonstrates our commitment to quality and will enable continued commercial expansion of the FLEX Vessel Prep System into the CE marked geographies." said Denis Harrington, VentureMed's President and CEO. "MDR certification demonstrates our commitment to quality and will enable continued commercial expansion of the FLEX Vessel Prep System into the CE marked geographies." saidDenis Harrington, VentureMed's President and CEO. About VentureMed Group, Inc. and…
PR Newswire
06/09/2023

Biogen Appoints Jane Grogan as Head of Research

BiogenInc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member of Biogen's Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. “Dr. Grogan is a pioneering scientist whose groundbreaking discoveries at Genentech helped pave the way for development of targeted autoimmune and oncology therapies. I believe Jane will be a strong asset to...
Nasdaq GlobeNewswire
06/09/2023

Bioretec has received Business Finland's R&D grant for developing coatings for…

As a part of this project, Bioretec is dedicated to researching and advancing the understanding of the use of biomaterials in the context of bone fracture fixation. The primary focus revolves around the development of coatings for RemeOs™ magnesium alloys. This innovation aims to enhance our ability to control and direct degradation processes, consequently also broadening the scope of indications for RemeOs™ products. As a part of this project, Bioretec is dedicated to researching and…
PR Newswire
06/09/2023

Study Validating MoA of Intranasal Foralumab in Alzheimer's Disease Published in…

The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment ofAlzheimer's disease (AD)”FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for human study in mild to moderate Alzheimer's DiseaseThe publication shows anti-CD3 monoclonal antibody (mAb) administered intranasally, ameliorates disease in a 3xTg model of Alzheimer's disease by targeting microglial activation in...
Nasdaq GlobeNewswire
06/09/2023

INTRODUCING TUMI 19 DEGREE FRAGRANCE

"We are thrilled to unveil the TUMI 19 Degree fragrance, expanding our fragrance portfolio to encompass a total of seven exquisite scents," says TUMI Creative Director Victor Sanz. "The intricately designed bottle reflects the same aesthetic principles found in our iconic 19 Degree travel collection – a harmonious blend of strength and fluidity, perfectly primed to accompany you on every journey." "We are thrilled to unveil the TUMI 19 Degree fragrance, expanding our…
PR Newswire
06/09/2023

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September…

MoonLake Immunotherapeutics to hosta Capital Markets Day onMonday , September 11 ZUG, Switzerland,September 6, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a Capital Markets Day for investors and analysts on Monday, September 11.The live webcast will be viewable from 11:30 am – 13:00 pm EDT/16:30 pm – 18:00 BST/17:30 – 19:00 pm CEST...
Nasdaq GlobeNewswire
06/09/2023

iTeos to Participate in Upcoming Investor Conferences

H.C. Wainwright 25 thAnnual Global Investment Conference Format: Fireside chat and one-on-one investor meetings Date: Wednesday, September 13, 2023 Time: 12:30 – 1:00 PM ETLocation: New York, N.Y. Cantor Global Healthcare Conference 2023Format: Fireside chat and one-on-one investor meetings Date: Wednesday, September 27, 2023 Time: 8:35 – 9:35 AM ET Location: New York, N.Y.A live webcast of each presentation will be available on the Investors section of the company's...
Nasdaq GlobeNewswire
06/09/2023

Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright…

Date: Tuesday, September 12, 2023 Time: 9:30 a.m. ET Location:Lotte New York Palace Hotel, Adams Room 4 thFloorWebcast Link:Available byclicking here Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright representative, or emailjpatton@oncolytics.ca. A live webcast of the Company's presentation will also be...
PR Newswire
06/09/2023

VIRBAC: MAR Weekly Report_VIRBAC SA_21 to 25 August 2023

Déclaration des transactions sur actions propres réalisées du 21/08/2023 au 25/08/2023BNP PARIBAS EXANE Présentation agrégée par jour et par marché Nom de l'émetteurCode Identifiant de l'émetteurJour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre d'actions)Prix pondéré moyen journalier d'acquisition des...
Nasdaq GlobeNewswire
06/09/2023

BIOVISER partners with LVC

"The times we're living in are transforming faster than a human mind is able to process," says Ivan D'Souza, CEO, BIOVISER. "Digital advancements are necessary for improving outreach, engagement, and experience. BIOVISER is excited to have its top-quality services complemented by LVC's superior digital solutions." "The times we're living in are transforming faster than a human mind is able to process," saysIvan D'Souza, CEO, BIOVISER. "Digital advancements are…
PR Newswire
06/09/2023

COMPASS Pathways announces publication of first study evaluating potential of AI…

Pyschopharmacology,which showed the results of a retrospective study that evaluates the potential of its AI technologies to support investigational COMP360 psilocybin treatment in treatment-resistant depression (TRD). The paper was published on August 22, 2023. The peer-reviewed paper shows the AI model has the potential to predict outcomes of the investigational COMP360 psilocybin treatment in people with TRD up to 12 weeks after treatment using recordings taken during the integration...
Nasdaq GlobeNewswire
06/09/2023

Alma welcomes the iconic Hollywood superstar, Kate Hudson as its new Global…

In collaboration under the theme "Beyond The Trend," Hudson and Alma aim to showcase the empowerment of embracing natural beauty, while Alma commits to delivering safe, effective, and evidence-based solutions. The campaign highlights Alma's award-winning products, including Alma Harmony, Soprano, Opus, PrimeX, which have inspired numerous individuals worldwide, fostering confidence and inner peace with their bodies. In collaboration under the theme "Beyond The Trend," Hudson…
PR Newswire
06/09/2023

BVI significantly expands its presence in Spain and Portugal acquiring Medical…

This strategic move builds on a period of significant momentum for BVI. The company has transformed into a broad manufacturer and supplier of market-leading, innovative solutions that provide an end-to-end range of products for cataract, retinal, and glaucoma diseases. This acquisition is another pivotal step in BVI's growth trajectory, which began to take form and accelerate since 2018. BVI's European footprint with direct sales representatives and infrastructure now spans all major...
Nasdaq GlobeNewswire
06/09/2023

Alma welcomes the iconic Hollywood superstar, Kate Hudson as its new Global…

In collaboration under the theme "Beyond The Trend," Hudson and Alma aim to showcase the empowerment of embracing natural beauty, while Alma commits to delivering safe, effective, and evidence-based solutions. The campaign highlights Alma's award-winning products, including Alma Harmony, Soprano, Opus, PrimeX, which have inspired numerous individuals worldwide, fostering confidence and inner peace with their bodies. In collaboration under the theme "Beyond The Trend," Hudson…
PR Newswire
06/09/2023

Tetra Pharm Technologies concludes preclinical testing of TPT0301 in preparation…

The In-Vivo study focuses on establishing the pharmacokinetic profile of TPT0301 in fasted rats over the course of 24 hours following gastro-intestinal (GI) administration. The candidate compound was formulated using Tetra Pharm Technologies' proprietary drug delivery technology and compared against a simplistic formulation principle commonly utilized for cannabinoids. "The In-Vivo tests establish essential pharmacokinetic information, demonstrating significantly faster onset of...
PR Newswire
06/09/2023

MedAlliance announces enrollment of First Patient in SELUTION SLR LOVE-DEB…

"The LOVE-DEB Study is a unique trial in which we are assessing the safety and efficacy of sirolimus DEB in de novo disease only in the large coronary arteries in routine clinical practice. We aim to recruit 300 patients over a period of 12 months across 10 centers in the UK. I am extremely delighted that we have kick-started the study by recruiting our first patient in the study at Wigan. I am very grateful for the invaluable support from all those who are involved in this study,"…
PR Newswire
06/09/2023

VALNEVA Declaration of shares and voting rights: August 31, 2023

VALNEVADeclaration of shares and voting rights August 31 , 2023__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment BDeclaration date: September 6, 2023 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of...
Nasdaq GlobeNewswire
06/09/2023

Safe Group announces the opening of rehabilitation proceedings

Safe Group announces the opening of rehabilitation proceedings Éragny-sur-Oise, Fleurieux sur l'Arbresle , France, on 6 September at08h30 CET –Safe (FR001400F1V2 – ALSAF), French group specialized in the design, manufacturing and distribution of ready-to-use medical devices for Spine surgeries, especially safe for vertebral fracture treated in emergency, announces the opening of rehabilitation proceedings.Following the press release...
Nasdaq GlobeNewswire
06/09/2023

Vitestro starts largest-scale clinical trial globally for its autonomous blood…

The first 350 patients have currently been enrolled the A.D.O.P.T. (Autonomous Optimization and Performance Tests for Blood Testing) Trial at study site Result Laboratorium in the Albert Schweitzer Hospital. Investigational partners, in addition to Result Laboratorium - Albert Schweitzer Hospital, are St. Antonius, OLVG Lab and Amsterdam UMC. Vitesro's device combines AI-based, ultrasound-guided 3D reconstruction with the robotic insertion of a needle, ensuring accurate, consistent...
PR Newswire
06/09/2023

Mendus Announces Participation in the H.C. Wainwright 25th Annual Global…

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that the Company will present a company presentation and participate in one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11 – 13, 2023 at the Lotte New York Palace Hotel in New York City. H.C. Wainwright 25th Annual Global Investment Conference: September 11th – 13thTitle: Mendus AB...
Nasdaq GlobeNewswire
06/09/2023
Altri  Comunicati